SYGNIS Pharma AG published its financial results for the first quarter of the fiscal year 2009/2010, which ended on 30 June 2009.
Dr. Alfred Bach, CEO of SYGNIS Pharma, said: "Our research and development programs remain fully on track. The phase II efficacy study for AX200 in ischemic stroke has been started as scheduled and continues as planned. In addition, we have continued to make good progress in our preclinical research projects especially with regard to KIBRA. The increase of operational expenses is in line with our planning and reflects the intensified research and development activities of the Company. We are strongly focusing the expenditures on our key value-driving research and development projects and will manage our cash resources efficiently to reach the next major milestones of these projects."